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Abstract The dopamine transporter gene, DAT1
(SLC6A3), has been studied extensively as a candidate gene
for attention-deficit/hyperactivity disorder (ADHD). Dif-
ferent alleles of variable number of tandem repeats
(VNTRs) in this gene have been associated with childhood
ADHD (10/10 genotype and haplotype 10-6) and adult
ADHD (haplotype 9-6). This suggests a differential asso-
ciation depending on age, and a role of DAT1 in modu-
lating the ADHD phenotype over the lifespan. The DAT1
gene may mediate susceptibility to ADHD through effects
on striatal volumes, where it is most highly expressed. In
an attempt to clarify its mode of action, we examined the
effect of three DAT1 alleles (10/10 genotype, and the
haplotypes 10-6 and 9-6) on bilateral striatal volumes
(nucleus accumbens, caudate nucleus, and putamen)
derived from structural magnetic resonance imaging scans
using automated tissue segmentation. Analyses were per-
formed separately in three cohorts with cross-sectional
MRI data, a childhood/adolescent sample (NeuroIMAGE,
301 patients with ADHD and 186 healthy participants) and
two adult samples (IMpACT, 118 patients with ADHD and
111 healthy participants; BIG, 1718 healthy participants).
Regression analyses revealed that in the IMpACT cohort,
and not in the other cohorts, carriers of the DAT1 adult
ADHD risk haplotype 9-6 had 5.9 % larger striatum vol-
ume relative to participants not carrying this haplotype.
This effect varied by diagnostic status, with the risk hap-
lotype affecting striatal volumes only in patients with
ADHD. An explorative analysis in the cohorts combined
(N = 2434) showed a significant gene-by-diagnosis-by-age
interaction suggesting that carriership of the 9-6 haplotype
predisposes to a slower age-related decay of striatal volume
specific to the patient group. This study emphasizes the
need of a lifespan approach in genetic studies of ADHD.
Keywords ADHD  DAT1 gene  Striatum  Volumetry
Introduction
Attention-deficit/hyperactivity disorder (ADHD) is a
common childhood-onset psychiatric disorder that features
symptoms of age-inappropriate inattention and/or impul-
sivity and hyperactivity. ADHD affects 5–6 % of children
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(Polanczyk et al. 2007) and frequently persists into adult-
hood (Faraone et al. 2006) causing a prevalence of ADHD
of between 2.5 and 4.9 % in the adult population (Simon
et al. 2009). The heritability of ADHD is around 0.8 in both
children (Faraone et al. 2005) and adults (Larsson et al.
2013). ADHD’s complex genetic etiology likely involves
multiple genes of small to moderate effect (Akutagava-
Martins et al. 2013).
The dopamine neurotransmission system has been an
important focus of genetic research in ADHD, since it is
the main site of action of stimulant drugs, the primary
pharmacological treatment for the disorder (Cortese 2012;
Faraone et al. 2014a). One of the most appealing and
extensively studied candidate genes for ADHD is the
dopamine transporter (DAT1) gene (official name SLC6A3)
(Faraone et al. 2005; Franke et al. 2012). The dopamine
transporter is a key determinant of synaptic dopamine
levels by regulating the reuptake of dopamine from the
extracellular space, thereby terminating its synaptic action
(Madras et al. 2005). The association between DAT1 and
ADHD was suggested in linkage and association studies
and is confirmed in meta-analyses (Franke et al. 2010;
Gizer et al. 2009; Li et al. 2006) showing small but sig-
nificant effects on the susceptibility to ADHD. Meta-
analyses of genetic association studies have indicated that
the 10-repeat allele of the 30 untranslated region (UTR)
variable number of tandem repeat (VNTR) is overrepre-
sented in children with ADHD (Gizer et al. 2009). More
recent studies suggested that the 10-repeat allele might
increase ADHD risk in children particularly in the context
of a haplotype with the 6-repeat allele of another VNTR in
intron 8 of the gene (Asherson et al. 2007; Brookes et al.
2008). A recent study also found an association between
this 10-6 haplotype and ADHD symptom measures in
nonclinical adults (Tong et al. 2015), but association
studies in clinical samples of adults with ADHD could not
confirm this relationship (Bru¨ggemann et al. 2007) and
reported an association of the 9-6 haplotype with adult
ADHD (Franke et al. 2008, 2010). Together, these findings
suggest a role for DAT1 in modulating the ADHD pheno-
type across the lifespan, with different associations
depending on age and diagnostic status.
The specific mechanisms by which DAT1 genetic vari-
ants affect the risk for ADHD are not well understood. Two
imaging genetics studies showed that genetic variation of
the DAT1 gene is associated with altered striatal volume,
which may contribute to ADHD susceptibility; the caudate
nucleus, a sub-region of the striatum, was found to be
smaller in children homozygous for the 10-repeat allele
(10/10) than in carriers of the 9-repeat allele (Durston et al.
2005; Shook et al. 2011). Although both studies did not
found an interaction between presence/absence of ADHD
and genotype, Durston et al. (2005) reported that the effect
of DAT1 genotype on caudate volume was only significant
in the subgroup of patients with ADHD. Studies investi-
gating the effect of the DAT1 gene on prefrontal gray
matter volume, cortical thickness, or white matter integrity
found no association between 10-repeat allele carriers (10/
10) and 9-repeat allele carriers (Durston et al. 2005; Hong
et al. 2015; Shaw et al. 2007), suggesting that this gene
primarily affects regions, where it is highly expressed (i.e.,
the striatum) (Ciliax et al. 1999; Durston et al. 2009).
The effect of the DAT1 gene on striatal volumes may
help explain smaller volumes of caudate nucleus and
putamen typically found in children with ADHD (Ellison-
Wright et al. 2008; Frodl and Skokauskas 2012; Nakao
et al. 2011; Valera et al. 2007). It has been shown that
volumetric differences in caudate nucleus and the putamen
gradually disappear with age (Castellanos et al. 2002; Frodl
and Skokauskas 2012; Greven et al. 2015; Maier et al.
2015; Nakao et al. 2011). The largest study to date by the
ENIGMA ADHD Working Group containing 1713 partic-
ipants with ADHD and 1529 controls show (among others)
reduced accumbens, caudate nucleus, and putamen volume
in ADHD. Case–control differences were most pronounced
in childhood confirming a model of delayed brain growth
and maturation (Hoogman et al., submitted). Nonetheless,
there is evidence from studies of adults with persistent
ADHD that differences in caudate nucleus volume
(Almeida Montes et al. 2010; Onnink et al. 2014; Proal
et al. 2011; Seidman et al. 2011; Shaw et al. 2014) and
putamen volume (Seidman et al. 2011; Shaw et al. 2014)
persist into adulthood.
To summarize, existing literature points to different
alleles of the DAT1 increasing susceptibility to categori-
cally defined ADHD from childhood to adulthood, with a
possible role of striatal volume in the pathway from gene to
disease. The evidence for an influence of DAT1 on striatal
volume is based on relatively small-sampled studies
[N = 59 in Shook et al. (2011) and N = 72 in Durston
et al. (2005)]. Moreover, these studies examined only one
variant of the DAT1 gene (10/10 homozygotes versus
9-repeat carriers), not taking into account the potentially
stronger effects of the two-VNTR haplotypes. Importantly,
they were conducted in children only and could not test
possible different effects of gene variation on striatal vol-
ume across the lifespan.
In the current study, we therefore set out to investigate
the effects of the three different DAT1 risk variants on
striatal brain volume (nucleus accumbens, caudate nucleus,
putamen) and the potential interaction with diagnostic
status and age. We defined the DAT1 10/10 genotype, the
10-6 haplotype, and the 9-6 haplotype as risk alleles, based
on associations with ADHD in children (10/10 genotype
and 10-6 haplotype) and in adults (9-6 haplotype),
respectively. Participants were derived from three cohorts
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with cross-sectional MRI data, a childhood/adolescent
sample (NeuroIMAGE, 301 patients with ADHD and 186
healthy controls) and two adult samples (IMpACT, 118
patients with ADHD and 111 healthy controls; BIG, 1718
healthy participants).
Methods
Participants
Participants of this study were derived from three distinct
cohorts. Ethical approval for all three was obtained, and all
participants provided written informed consent.
A total of 487 subjects (301 unrelated patients with
ADHD and 186 control participants) were derived from the
NeuroIMAGE cohort of families with ADHD and control
families (http://www.neuroimage.nl) (von Rhein et al.
2015). Only one individual per family was included thus
(un)affected siblings were not included in this study. Par-
ticipants were recruited at VU University Amsterdam,
Amsterdam, and Radboud University Medical Center,
Nijmegen. Inclusion criteria were an age between 8 and
30 years; European Caucasian descent; intelligence quo-
tient (IQ) greater than or equal to 70; and no diagnosis of
autism, epilepsy, general learning difficulties, brain disor-
ders, and known genetic disorders. All participants were
evaluated with a semi-structured diagnostic interview
assessing ADHD, oppositional defiance disorder (ODD),
and conduct disorder (CD). For further details on diag-
nostic assessment, see von Rhein et al. (2015).
A total of 229 subjects (118 adult patients with ADHD
and 111 control participants) were included from the Dutch
cohort of the International Multicentre persistent ADHD
CollaboraTion, IMpACT (http://www.impactadhdge
nomics.com; (Franke et al. 2010; Onnink et al. 2014).
Participants were recruited at Radboud University Medical
Center, Nijmegen. All participants were evaluated with
semi-structured diagnostic interviews for assessing ADHD
and axis I and axis II disorders. For details on diagnostic
assessment, see Onnink et al. (2014). Inclusion criteria
were an age between 18 and 65 years; European Caucasian
descent; IQ greater than or equal to 70; no diagnosis of
psychosis, alcohol or substance use disorder in the last
6 months, current major depression, neurological and
sensorimotor disorders. An exclusion criterion for the
control participants was a current neurological or psychi-
atric disorder.
A total of 1718 control participants were included from
the Cognomics Initiative Resource, the Brain Imaging
Genetics (BIG) study (http://www.cognomics.nl). This
ongoing study started in 2007 and is a collection of healthy
volunteers, many with a high education level, who
participated in studies at the Donders Centre for Cognitive
Neuroimaging (DCCN) of the Radboud University in
Nijmegen (Guadalupe et al. 2014). The self-reported
healthy individuals underwent anatomical (T1-weighted)
magnetic resonance imaging (MRI) scans, usually as part
of their involvement in diverse smaller-scale studies at the
DCCN.
Genotyping
In all three cohorts, DNA was isolated from EDTA blood
samples or saliva samples using standard procedures.
Genotyping of the 40 base pair VNTR in the 30UTR and the
VNTR in intron 8 of DAT1/SLC6A3 was carried out at the
department of Human Genetics of the Radboud University
Medical Center, Nijmegen as is described earlier (Franke
et al. 2010). Haplotypes were calculated using the Haplo-
stats package (Rversion 2.12.0) (Schaid et al. 2002).
Image acquisition and segmentation
MRI data in NeuroIMAGE were acquired at two locations
(VU University Amsterdam, Amsterdam, and Radboud
University Medical Center, Nijmegen) using two similar
1.5 Tesla (T) scanners (Sonata and Avanto; Siemens
Medical Systems, Erlangen, Germany) with closely mat-
ched scan protocols (von Rhein et al. 2015). MRI data in
IMpACT were acquired with a 1.5T scanner (Avanto;
Siemens Medical Systems, Erlangen, Germany). For Neu-
roIMAGE, GRAPPA2 (generalized autocalibrating partial
parallel acquisition) and for IMpACT magnetization pre-
pared rapid gradient echo sequence (MPRAGE) sequences
were used. For NeuroIMAGE and IMpACT, all scans
covered the entire brain and had a voxel size of
1 9 1 9 1 mm (176 sagittal slices; repetition time =
2730 ms; echo time = 2.95 ms; inversion time =
1000 ms; flip angle = 7; field of view = 256 mm). MRI
data in BIG were acquired with either a 1.5T (Sonata and
Avanto; Siemens Medical Systems, Erlangen, Germany)
(N = 923) or with a 3T Siemens scanner (Trio and Tim-
Trio; Siemens Medical Systems, Erlangen, Germany)
(N = 796). Given that images were acquired during several
smaller scale studies, the parameters used were slight
variations of a standard T1-weighted sequence (MPRAGE;
voxel size of 1 9 1 9 1 mm). The most common varia-
tions in the TR/TI/TE/saggital-slices parameters were the
following: 2300/1100/3.03/192, 2730/1000/2.95/176,
2250/850/2.95/176, 2250/850/3.93/176, 2250/850/3.68/
176, 2300/1100/3.03/192, 2300/1100/2.92/192, 2300/1100/
2.96/192, 2300/1100/2.99/192, 1940/1100/3.93/176 and
1960/1100/4.58/176. Such slight variations in these imag-
ing parameters have been shown not to affect the reliability
of morphometric results (Jovicich et al. 2009).
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Whole-brain volume
Normalization, bias correction, and segmentation into gray
matter, white matter, and cerebrospinal fluid volumes were
performed using the unified procedure of the VBM 8.1
toolbox (http://dbm.neuro.uni-jena.de/vbm/) in SPM (de-
fault settings). Total gray and white matter volumes were
calculated by summation of their tissue probability maps.
Total brain volume was the sum of total gray and white
matter volumes.
Striatal volumes
Automated FIRST (FMRIB’s Integrated Registration and
Segmentation Tool) subcortical segmentation was applied
to estimate left and right hemisphere volumes of the
nucleus accumbens, caudate nucleus, and putamen. The
ENIGMA protocol (http://enigma.ini.usc.edu/protocols/
imaging-protocols/) for the FIRST module (version 1.2) of
FSL (version 4.1.5) was followed. FIRST is part of
FMRIB’s Software Library and performs registration and
shape modeling of the just-mentioned regions in Montreal
Neurological Institute 152 standard space (Patenaude et al.
2011). Total striatal volume was the sum of left and right
volumes of the nucleus accumbens, caudate nucleus, and
putamen.
Statistical analyses
Brain volumetric measures were normally distributed, and
outliers defined as more than three standard deviations
greater than or less than the mean were removed. Overall,
there were few outliers (1–5 individuals per volume). For
each cohort independently, the effect of three variants of
the DAT1 gene on striatal volumes were examined by
comparing: (1) carriers of the 10/10 genotype with all non-
carriers, (2) carriers of at least one copy of the 10-6 hap-
lotype with all non-carriers, and (3) carriers of at least one
copy of the 9-6 haplotype with all non-carriers. Associa-
tions between the three risk variants of the DAT1 gene and
striatal volumes were examined using regression analyses
in SPSS (IBM SPSS v.20). Regression analyses included
variant of the DAT1 gene, diagnostic status, and the
interaction between risk variant and diagnostic status
(DAT1 variant 9 diagnostic status) as predictors and total
striatal volume as dependent measure. Included covariates
were age, gender, and total brain volume (sum of white and
gray matter); for the NeuroIMAGE and BIG cohorts,
additional covariates were scanner location and type (for
NeuroIMAGE: Amsterdam or Nijmegen; for BIG: 1.5T or
3.0T); for the BIG cohort with healthy participants, diag-
nostic status was dropped from the model. Centering of
variables was used (Bradley and Srivastava 1979). First, we
tested the interaction between DAT1 variant and diagnostic
status. Whenever this interaction term was significant
(p\ .05), we analyzed the results separately by diagnostic
status. If not significant, this interaction was dropped from
the model. For significant main effects of the three risk
variants, we performed post hoc sensitivity analyses. Cor-
recting with covariates in a regression analysis is only
appropriate if covariate means or distributions are equal
between groups (Miller and Chapman 2001). Therefore,
sensitivity analyses in a matched subsample were per-
formed for the instances in which covariates differed
between groups. Automatic case–control matching was
performed with the FUZZY extension for SPSS (http://
www.spss.com/devcentral). Sensitivity analyses were per-
formed to investigate the effect of the risk variant on each
subregion of the striatum (left and right volumes of nucleus
accumbens, caudate nucleus, and putamen). Additionally,
we investigated the possible effect of medication on the
results by including lifetime medication use (yes or no) to
the model. To explore potential interactions between DAT1
variant, diagnostic status, and age on striatal volume
(DAT1 variant 9 diagnostic status 9 age), we combined
the samples from the three cohorts into one sample in order
to maximize the age range. Then, striatal volume was
adjusted for the same covariates as mentioned above,
except age, using a linear regression analysis from which
standardized residuals were computed and were used in the
analyses (Walhovd et al. 2005). To visualize potential age
effects, the residuals were also plotted.
Correction for multiple testing
To correct for multiple testing, Bonferroni correction was
applied by dividing the significance level by the number of
independent tests. In three cohorts (NeuroIMAGE,
IMpACT, BIG), we examined the effects of three alleles/
genotypes (10/10, 10-6 haplotype, 9-6 haplotype) on stri-
atal volume. We performed a total of nine tests and set the
multiple-testing adjusted p value at 0.05/9 = 0.0055. Post-
hoc sensitivity analyses of findings surviving multiple-
testing correction used the nominal significance level
(p\ .05).
Results
Demographics
Demographics for ADHD patients and control participants
are displayed for the NeuroIMAGE, IMpACT, and BIG
cohorts separately in Table 1. From the NeuroIMAGE
cohort, the 301 patients with ADHD and 186 control par-
ticipants were evenly distributed across groups based on
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VNTR genotypes (10/10) and DAT1 haplotypes (10-6
haplotype or 9-6 haplotype). In this cohort, patients were
significantly older compared with the control participants
[t(1, 485) = 2.21, p = .03], and gender distribution was
significantly different, with males predominating in the
ADHD group and females in the control group
(v2 = 16.19, p\ .001). From the IMpACT cohort, 118
patients with ADHD and 111 control participants were
included, for which no differences in the distribution of
DAT1 10/10 genotype and DAT1 10-6 haplotype were
observed. The 9-6 haplotype showed a higher prevalence
in patients compared with controls (v2 = 5.21, p = .023;
see Table 1), as was reported previously in this cohort
(Hoogman et al. 2012). From the BIG cohort, 1718 healthy
participants were included. Genotype distributions did not
deviate from Hardy–Weinberg equilibrium, and frequen-
cies were as expected in Caucasian samples (Franke et al.
2010).
Demographics for 10/10, 10-6, and 9-6 carrier and
respective non-carrier groups are displayed for the Neu-
roIMAGE, IMpACT, and BIG cohorts separately in sup-
plementary Tables 1, 2, and 3. In the IMpACT cohort,
gender distribution was significantly different between
DAT1 10/10 carriers and non-carriers (v2 = 4.47, p = .03;
supplementary Table 1), with males predominating in the
DAT1 10/10 group and females in the non-DAT1 10/10
group. Gender distribution was also significantly different
between DAT1 9-6 carriers and non-carriers (v2 = 5.16,
p = .02; supplementary Table 3), with males predomi-
nating in the DAT1 9-6 group and females in the non-
carriers.
Main and interaction effects of DAT1 variants
on total striatum volume
For each cohort, mean total striatum volumes corrected for
covariates are shown in Table 2. In the IMpACT cohort,
subjects carrying at least one copy of the 9-6 risk haplotype
showed a 5.9 % larger striatum volume (1.09 ml larger)
than subjects carrying none (b = 1.09; 95 % CI 0.63–1.56;
p = .00001) (Tables 2, 3). No effects of the DAT1 variant
(combinations) were observed in the NeuroIMAGE or BIG
cohorts.
In the IMpACT cohort, an interaction between the
DAT1 9-6 haplotype and diagnostic status on striatal vol-
ume was significant (p = .02). Testing patients with
ADHD and controls separately revealed that patients car-
rying at least one copy of the DAT1 9-6 haplotype had
larger striatum volume (7.4 %; 1.37 ml; b = 1.37; 95 %
CI 0.80–1.94; p = .00001), while this effect was not sig-
nificant in the control group (3.0 %; 0.57 ml; b = 0.57;
95 % CI -0.25 to 1.39; p = .17) (Table 3 and supple-
mentary Table 5). Another significant interaction alsoT
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observed in the IMpACT cohort was between diagnostic
status and DAT1 10/10 genotype (p = .005). Post-hoc
analyses revealed that patients homozygous for the 10R
allele (10/10 carriers) had smaller striatum volume than 9R
carriers (-3.5 %; 0.64 ml; b = -0.64; 95 % CI -1.14 to
-0.14; p = .013), while this effect was not present in the
control group (1.4 %; 0.36 ml; b = 0.36; 95 % CI -0.17
to 0.89; p = .18) (Table 3 and supplementary Table 4).
Sensitivity analyses
In the NeuroIMAGE cohort, gender distribution and age
were significantly different between patients and controls
(Table 1). We therefore examined the effect of the three
variants of the DAT1 gene on striatal volume in a subample
that was matched for gender and age (supplementary
Table 6). The results in this matched subsample (supple-
mentary Table 7) supported the results of the unmatched
sample (Table 3). In the IMpACT cohort, gender distri-
bution was significantly different between DAT1 10/10
carriers and non-carriers (supplementary Table 1) and
between DAT1 9-6 carriers and non-carriers (supplemen-
tary Table 3). However, analysis of the effects of these two
DAT1 variants on striatal volume in a gender-matched
subsample (supplementary Table 8) confirmed the results
observed in the full sample (supplementary Table 9 and
Table 3). The effect of the DAT1 9-6 haplotype on striatal
volume found in the IMpACT cohort was the strongest
effect observed, surviving multiple-testing correction, and
was investigated further. Sensitivity analyses in the
IMpACT cohort were performed to examine the effect of
the DAT1 9-6 haplotype on the six subregions of the
striatum independently (left and right volumes of nucleus
accumbens, caudate nucleus, and putamen). Compared to
subjects carrying no copies of the 9-6 risk haplotype,
subjects carrying at least one copy of the risk haplotype had
larger right putamen volume (6.2 %; 0.33 ml; b = 0.33;
95 % CI 0.17–0.48; p = .00005), larger left putamen
(6.1 %; 0.32 ml; b = .32; 95 % CI 0.14–0.49; p = .0004),
larger right caudate nucleus (5.9 %; 0.22 ml; b = 0.22;
95 % CI 0.09–0.35; p = .001), larger left caudate nucleus
(5.5 %; 0.20 ml; b = 0.20; 95 % CI 0.07–0.33; p = .002),
and larger right nucleus accumbens (5.8 %; 0.03 ml;
b = 0.03; 95 % CI 0.01–0.06; p = .04). Findings were not
significant for left nucleus accumbens (p[ .05) (supple-
mentary Table 10). Testing the effect of the DAT1 9-6
haplotype on the six subregions of the striatum for patients
with ADHD and controls separately revealed similar results
as above in the patients, while effects were non-significant
in controls (all p values[.05) (supplementary Table 11).
Furthermore, rerunning analyses including medication use
(yes or no) in the model yielded highly similar results
(supplementary Table 12).
Age effects of the DAT1 9-6 haplotype
To explore potential interactions between the DAT1 9-6
haplotype, diagnostic status, and age on total striatum
volume, we combined the samples from the three cohorts
into one sample in order to maximize the age range. Total
Table 3 Regression of binary genotypes on total striatal volume
NeuroIMAGE (N = 487) IMpACT (N = 229) BIG (N = 1718)
b (95 % CI), p valuea b (95 % CI), p valuea b (95 % CI), p valuea
DAT1 10/10 0.22 (-0.04; 0.48), .09 -0.16 (-0.53; 0.20), .38 -0.03 (-0.15; 0.09), .57
Diagnostic status 0.22 (-0.05; 0.49), .12 -0.29 (-0.62; 0.07), .11
Diagnostic status 9 DAT1 10/10 ns -1.03 (-1.74; -0.32), .005
DAT1 10-6 -0.35 (-0.86; 0.16), .18 -0.41 (-1.04; 0.22), .21 0.02 (-0.19; 0.24), .84
Diagnosis 0.24 (-0.34; 0.51), .09 -0.28 (-0.63; 0.08), .13
Diagnostic status 9 DAT1 10-6 ns ns
DAT1 9-6 -0.22 (-0.57; 0.13), .21 1.09 (0.63; 1.56), .00001b 0.06 (-0.11; 0.23), .47
Diagnosis 0.24 (-0.33; 0.51), .09 -0.40 (-0.74; -0.05), .024
Diagnostic status 9 DAT1 9-6 ns 1.14 (0.17; 2.11), .021
For the NeuroIMAGE and IMpACT cohorts, interactions with genotype and diagnostic status (genotype 9 diagnostic status) were tested and
removed when not nominal significant (p\ .05)
Results from the final regression model examining associations between binary genotype (risk carriers vs non-risk carriers) and brain volumes.
Boldface indicates results surviving multiple-testing correction
ns not significant
a For main effects, b (unstandardized regression coefficient) is equal to the difference in mean brain volumes (in ml) between the genotype
groups adjusted for covariates in the model. Included covariates were diagnostic status, age, gender, total brain volume; for the NeuroIMAGE
and BIG cohorts, covariates also included scanner type; for the BIG cohort, diagnosis was dropped from the model
b b = 1.09 denotes that 9-6 carriers had a 1.09 ml larger striatum volume than non 9-6 carriers
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striatal volume was regressed on covariates of no interest
and the standardized residuals were used for analysis. In
this mega-analysis design, the 3-way interaction between
the 9-6 haplotype, diagnostic status, and age on striatal
volume was significant (p = .0001). Testing patients with
ADHD and controls separately revealed that the interaction
between DAT1 9-6 haplotype and age was significant in the
patient group (p = .00004) but not in the control group
(p = .94) (Fig. 1).
Discussion
In the current study, the effect of the dopamine transporter
gene DAT1/SLC6A3 on striatal brain volume was investi-
gated in children and adults with ADHD and healthy par-
ticipants in three different cross-sectional cohorts. In the
adult case–control cohort IMpACT, carriers of the 9-6
haplotype, the risk allele for adult ADHD, had larger stri-
atal volume than participants not carrying this haplotype.
This effect varied by diagnostic group, with the risk hap-
lotype affecting striatal volumes only in patients with
ADHD and not in the healthy participants from this cohort.
Consistent with this, the effect was not found in the BIG
cohort of adult healthy participants. It was also not
observed in the case–control children/adolescents cohort
from NeuroIMAGE. Through an interaction analysis
within the IMpACT cohort, also the 10/10 genotype was
shown to affect striatal volume in patients only when
compared to carriers of 9R allele(s), which was a smaller
effect than for the 9-6 haplotype (and probably was just the
other side of the same coin).
The finding in the IMpACT cohort showing smaller
striatal volume in adult ADHD patients homozygous for
the 10R allele (10/10 carriers) compared to 9R carriers is
consistent with previous studies performed in children
(Durston et al. 2005; Shook et al. 2011). However, as 84 %
of the 9R carriers consisted of 9-6 haplotype carriers, this
effect might be driven by the subgroup of 9-6 haplotype
carriers. Indeed, the regression coefficient of -0.64
(p = .013, N = 118) (supplementary Table 4) dropped to
-0.074 (p = .78, N = 92) when the 9-6 haplotype carriers
(N = 26) were excluded from the analysis (data not
shown). The diagnosis-specificity of DAT1 only affecting
striatal volume in the subgroup of patients with ADHD was
also suggested in the previous study by Durston et al.
Fig. 1 Age-related changes in the striatal volume. a Regression plots
visualizing the 3-way interaction (DAT1 genotype 9 diagnostic
status 9 age) by plotting the relationships between age and total
striatal volume for DAT1 9-6 haplotype carriers and non-carriers
separately for controls and ADHD patients. b Same data as in a
although now visualized using separate age groups. The figure sug-
gests that carriership of the 9-6 haplotype predisposes to a slower age-
related decay of striatal volume in patients with ADHD
912 A. M. H. Onnink et al.
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(2005). Larger striatal volume in adult carriers of the DAT1
risk haplotype 9-6 for adult ADHD may represent com-
pensatory mechanisms for the increased expression/activity
of the dopamine transporter, which has been found in
9-repeat allele carriers (Faraone et al. 2014b). The
increased levels of DAT in these individuals might lead to
more efficient clearing of extracellular dopamine, yielding
lower extracellular levels and reduced dopamine signaling
(Faraone et al. 2014b). Importantly, a study by Spencer and
coworkers showed that an ADHD diagnosis made an
additional, independent contribution to DAT binding
(Spencer et al. 2013). The diagnosis-specificity of our
findings may thus reflect an interaction between genetic
and environmental risk factors, where cumulative effects
allow for a bigger impact of DAT1 genotype on striatal
volume in the patients. We emphasize, nonetheless, that
replication of our findings is needed before firm conclu-
sions can be drawn.
Our explorative 3-way interaction analysis in the cohorts
combined (N = 2434) investigating the effect DAT1 9-6
haplotype, diagnostic status, and age suggests that carri-
ership of the 9-6 haplotype predisposes to a slower age-
related decay of striatal volume, which is specific for
ADHD patients (Fig. 1). Importantly, age effects have
shown a differential decay of DAT1 expression for different
genotypes (Shumay et al. 2011), which may be consistent
with the compensation hypothesis mentioned above. Shu-
may et al. demonstrated that 9-repeat homozygotes showed
the steepest decline of DAT availability with increasing
age. Great care is needed in interpreting the age effects we
observed, as this is a cross-sectional study. Interestingly, a
recent study suggests that individuals can meet symptom
criteria for ADHD as adults without having a history of
childhood ADHD (Moffitt et al. 2015). Although this study
by Moffitt et al. is in need of replication, our results may
suggest that carriership of the DAT1 9-6 haplotype might
be a mechanism contributing to the emergence of new
cases of ADHD during adulthood. However, to replicate
our age-dependent effect and to explore this more fully,
analysis of longitudinal MRI data is required.
The functional implications of larger striatal volume for
the pathophysiology of adult ADHD remain to be investi-
gated. As smaller caudate volume in male patients with
ADHD has been associated with an increased number of
hyperactivity/impulsivity symptoms (Onnink et al. 2014),
larger striatum volume in a subgroup of ADHD patients
may be linked to neurobiological processes that go along
with the reported age-dependent decline in hyperactivity/
impulsivity symptoms in people with ADHD (Biederman
et al. 2000). Increased volume may also reflect compen-
satory ‘hypertrophy’ because of reduced dopamine neuro-
transmission (see above).
Our findings should be viewed in the light of certain
strengths and limitations. A clear strength was the inves-
tigation of haplotypes of DAT1 in addition to the 30UTR
VNTR genotype variants in a large sample including
patients with ADHD and healthy individuals at different
ages. This case–control design maximized the variance in
the phenotype and may have magnified gene effects. A
strong limitation was the cross-sectional MRI study design,
especially since the participants of this study were partly
derived from different cohorts. Another limitation was the
restricted availability of data at early childhood age and
late adult age, which reflects insufficient focus of imaging
research in our field on such age groups. The develop-
mental trajectories our data propose need to be confirmed
in additional studies, optimally from longitudinal studies
including data across a wide age range collected using the
same study protocol.
In summary, our cross-sectional findings showed that
adult patients with ADHD carrying the DAT1 9-6 risk
haplotype for adult ADHD had increased striatal volume.
Furthermore, based on our exploratory analysis on age
effects, we hypothesize that ADHD patients carrying the
9-6 haplotype follow a different trajectory of brain devel-
opment over the lifespan than those ADHD patients not
carrying this haplotype. These findings are in need of
replication, preferably using longitudinal designs. Clarify-
ing the nature of the involvement of DAT1 variants in brain
development would provide a key step towards under-
standing part of ADHD’s pathophysiology. The present
results demonstrate the importance of taking into account
interindividual variability, as indexed by DAT1 haplotype,
presence of an ADHD diagnosis, and age, when assessing
striatal volume effects in ADHD.
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